Insider Buying: Surrozen (NASDAQ:SRZN) Major Shareholder Buys 1,190 Shares of Stock

Surrozen, Inc. (NASDAQ:SRZN) major shareholder Tcg Crossover Gp Ii, Llc purchased 1,190 shares of the business’s stock in a transaction that occurred on Monday, March 16th. The shares were purchased at an average price of $24.99 per share, for a total transaction of $29,738.10. Following the completion of the acquisition, the insider directly owned 675,613 shares in the company, valued at $16,883,568.87. The trade was a 0.18% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Tcg Crossover Gp Ii, Llc also recently made the following trade(s):

• On Friday, March 13th, Tcg Crossover Gp Ii, Llc bought 35,433 shares of Surrozen stock. The shares were acquired at an average price of $24.88 per share, with a total value of $881,573.04.
• On Thursday, March 12th, Tcg Crossover Gp Ii, Llc bought 12,374 shares of Surrozen stock. The shares were acquired at an average price of $24.99 per share, with a total value of $309,226.26.
• On Thursday, February 12th, Tcg Crossover Gp Ii, Llc purchased 1,093 shares of Surrozen stock. The stock was acquired at an average price of $23.86 per share, for a total transaction of $26,078.98.
• On Wednesday, February 11th, Tcg Crossover Gp Ii, Llc purchased 17,763 shares of Surrozen stock. The shares were acquired at an average cost of $23.57 per share, with a total value of $418,673.91.
• On Tuesday, February 3rd, Tcg Crossover Gp Ii, Llc acquired 4,355 shares of Surrozen stock. The shares were acquired at an average price of $21.94 per share, with a total value of $95,548.70.
• On Monday, February 2nd, Tcg Crossover Gp Ii, Llc acquired 731 shares of Surrozen stock. The stock was acquired at an average cost of $21.38 per share, for a total transaction of $15,628.78.
• On Friday, January 30th, Tcg Crossover Gp Ii, Llc acquired 4,271 shares of Surrozen stock. The stock was acquired at an average cost of $21.39 per share, for a total transaction of $91,356.69.

Surrozen Stock Performance

SRZN stock traded up $0.29 during midday trading on Monday, reaching $25.50. The company’s stock had a trading volume of 33,763 shares, compared to its average volume of 112,361. Surrozen, Inc. has a 1 year low of $5.90 and a 1 year high of $29.59. The firm has a market capitalization of $218.56 million, a price-to-earnings ratio of -1.14 and a beta of 0.53. The stock has a fifty day simple moving average of $23.46 and a two-hundred day simple moving average of $18.20.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on SRZN. Wall Street Zen raised shares of Surrozen to a “sell” rating in a research report on Friday, November 28th. Cantor Fitzgerald began coverage on shares of Surrozen in a research report on Thursday, February 19th. They set an “overweight” rating and a $40.00 target price on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Surrozen in a report on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $36.00.

Institutional Investors Weigh In On Surrozen

Large investors have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. lifted its position in shares of Surrozen by 50.0% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 1,500 shares of the company’s stock worth $34,000 after purchasing an additional 500 shares during the period. Persistent Asset Partners Ltd purchased a new position in Surrozen during the fourth quarter valued at approximately $99,000. Citadel Advisors LLC raised its stake in Surrozen by 32.8% in the third quarter. Citadel Advisors LLC now owns 13,875 shares of the company’s stock worth $179,000 after buying an additional 3,424 shares in the last quarter. Marshall Wace LLP purchased a new stake in Surrozen during the fourth quarter worth $247,000. Finally, Geode Capital Management LLC boosted its position in Surrozen by 22.6% during the 2nd quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock valued at $277,000 after acquiring an additional 5,702 shares in the last quarter. Institutional investors own 66.57% of the company’s stock.

Surrozen Company Profile

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.